Using 68-Ga DOTATATE PET/MRI to Diagnose and Manage Certain Brain Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of 68Ga-DOTATATE PET/MRI in diagnosing and managing somatostatin receptor-positive CNS tumors, particularly meningioma. It aims to determine if this imaging technique can accurately distinguish between tumor recurrence and post-treatment changes. The study includes patients who have undergone resection for these tumors and assesses the utility of this method in detecting additional lesions and evaluating residual tumor extent. The research builds on prior findings that suggest this imaging approach may provide significant insights into tumor management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥ 18 years of age
* Diagnosis of meningioma based on pathology reports and suspected recurrence or residual disease based on standard-of-care MRI
* Additionally, patients with other somatostatin receptor 2 positive brain tumors, including esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma, and SSTR-positive systemic cancers metastatic to the brain will be considered for the purposes of obtaining feasibility data
* As the investigator's institution, PET/MRI scanner utilizes a 3 Tesla (T) magnet, patients who may be ineligible to undergo 3T MRI but may undergo 1.5 Tesla (T) MRI, will undergo a 1.5T MRI as per clinical standard-of-care and a Ga68-DOTATATE PET/CT with the PET portion to be fused with the 1.5T MRI utilizing fusion software.

Exclusion Criteria:

* Contraindications to gadolinium-based contrast agent
* History of allergic reaction to Gallium-68-DOTATATE
* Pregnancy

Where it's running

• Weill Cornell Medicine
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Jana Ivanidze, MD/Ph.D — Weill Medical College of Cornell University
• Study coordinator: Jana Ivanidze, MD/Ph.D
• Email: jai9018@med.cornell.edu
• Phone: 212-746-4587

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents

  This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.

  Recruiting Phase 1/2 Fundación de investigación HM · Boadilla del Monte, Madrid · NCT06607692

• Panitumumab-IRDye800 for guiding brain tumor surgery

  A tiny dose of panitumumab-IRDye800 is tested to see if it helps visualize brain tumors during surgery in adults.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07493447

• Investigating the effects of endoscopic skull base surgery on smell

  This study tests how endoscopic skull base surgery affects the sense of smell in patients to better understand any smell-related problems that might happen after the surgery.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Leuven, Vlaams-Brabant and 2 other locations · NCT06874426

• Proton versus photon radiation for adults with primary brain tumors

  This trial will test whether proton beam radiation causes fewer long-term side effects than standard photon (X-ray) radiation in adults aged 18–70 with primary brain tumors who are expected to live more than five years.

  Recruiting Tata Memorial Centre · Mumbai · NCT06831461

• Pharmacoscopy-guided treatment for refractory brain tumors

  This trial tests whether personalized drug testing on a patient’s tumor cells can guide treatment choices for adults with hard-to-treat brain cancers like glioblastoma.

  Recruiting Phase 2 University of Zurich · Basel, Basel-Landschaft and 2 other locations · NCT06804655

• Impact of Radiotherapy on Neurocognition in Brain Tumor Patients

  This study is testing how radiotherapy affects thinking and memory in adults with brain tumors over time to see if certain treatments lead to cognitive decline.

  Recruiting at 3 sites Universitaire Ziekenhuizen KU Leuven · Ghent and 2 other locations · NCT05727605

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.